Monday, 31 August 2026European Markets

BIOTALYS Stock Was Up By 16.95% On Tuesday

Loading stream...

(VIANEWS) - The Market ended the session with BIOTALYS (BTLS.BR) jumping 16.95% to €4.90 on Tuesday, after five successive sessions in a row of losses. BEL 20 slid 0.39% to €3,721.87, following the last session's upward trend on what was a somewhat bearish trend exchanging session today.

About BIOTALYS

Biotalys NV, an agricultural technology company, discovers and develops novel biological products for the protection of food and crops. It primarily develops biofungicides, bioinsecticides, and biobactericides. The company was formerly known as Agrosavfe NV. Biotalys NV was incorporated in 2013 and is headquartered in Gent, Belgium.

Earnings Per Share

As for profitability, BIOTALYS has a trailing twelve months EPS of €-0.76.

Volatility

BIOTALYS's last week, last month's, and last quarter's current intraday variation average was a negative 2.73%, a positive 1.58%, and a positive 5.92%.

BIOTALYS's highest amplitude of average volatility was 2.73% (last week), 4.73% (last month), and 5.92% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOTALYS's stock is considered to be overbought (>=80).

Volume

Today's last reported volume for BIOTALYS is 43992 which is 11.07% below its average volume of 49473.

More news about BIOTALYS (BTLS.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com